Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The investigators propose to perform a clinical randomized trial to evaluate the effect of a frozen-thawed embryo transfer and a fresh embryo transfer on pregnancy and implantation rates; with the added benefit of a blastocyst biopsy and whole chromosome analysis by Next Generation Sequencing (NGS).


Options:
A: Inclusion Criteria:

* Undergoing In-vitro fertilization (IVF) treatment
* Number of previous failed embryo transfers ≤ 2
* Permanent living in Viet Nam
* Ovarian hyperstimulation with Gonadotropin releasing hormone (GnRH) antagonist protocol
* Eligible for embryo transfer (ET) on day 3
* Having at least one top-quality embryo on day 3.
* Number of embryos transferred ≤ 2
* Willing to participate in the study
* Not to participate in another IVF study at the same time

Exclusion Criteria:

* women with polycystic ovary syndrome
* In vitro maturation (IVM) cycles
* Oocyte donation cycles
* Using GnRH agonist for triggering
B: Inclusion Criteria:

* Women \[18 - 40\[years of age (according to date of birth at time of informed consent) who are eligible for ovarian stimulation and ART treatment, including intracytoplasmic sperm injection (ICSI)
* Absence of anatomical abnormalities of the reproductive tract that would interfere with implantation or pregnancy
* Absence of any medical condition in which pregnancy is contraindicated
* Motile, ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed). Intracytoplasmic sperm injection (ICSI) will be allowed during this trial
* Body mass index 18 to 35 kg/m2, inclusive
* Able to understand the study
* Affiliation with a social security scheme
* Dated and signed inform consent

Exclusion Criteria:

* Altered ovarian reserve (Day3: FSH \>12 UI/l; AMH\<1,0 ng/ml; AFC\<8)
* History or presence of tumours of the hypothalamus or pituitary gland
* Presence of non isolated uni- or bilateral hydrosalpinx
* Abnormal gynaecological bleeding of undetermined origin
* Contraindication to being pregnant and/or carrying a pregnancy to term
* Known infection with human immunodeficiency virus, active hepatitis B or C virus in the female or male partner
* History or presence of ovarian, uterine or mammary cancer
* Known allergy or hypersensitivity to human gonadotropin preparations or to compounds that are structurally similar to any of the other medications administered during the trial
* Substance abuse that would interfere with trial conduct, as determined by the investigator
* Use of testicular or epididymal sperm
* Pregnant patient, nursing patient
* Participation in another ART clinical trial within the past 30 days
* Women who have risk to develop severe ovarian hyperstimulation syndrome (OHSS) during controlled ovarian stimulation (COS) defined as ≥ 18 follicles measuring 10 - 14 mm on the day of triggering
* Women with less than 3 follicles ≥ 15 mm on the triggering day or the day before the triggering
* Women with premature progesterone elevation during COS ( ≥1.5 ng/ml)
* Women with uterine polyps diagnosed during COS
* Participation with another interventional study involving human subjects
C: Inclusion Criteria:

* AMH (Anti-Müllerian hormone) \> 6.28 pmol/L (Roche Elecsys assay)
* Female age 18 years to less than 40 years
* 1, 2 or 3 IVF/ICSI cycle with oocyte aspiration
* Regular menstrual cycle between 24 and 35 days
* BMI between 18 and 35
* Two ovaries
* Can and will sign informed consent

Exclusion Criteria:

* Women who do not fulfil the inclusion criteria
* Endometriosis stage III to IV
* Ovarian cysts with diameter \> 30 mm at day of start of stimulation
* Submucosal fibroids
* Women with severe co-morbidity (IDDM, NIDDM, gastrointestinal, cardiovascular, pulmonary, liver or kidney disease)
* Dysregulation of thyroid disease
* Not danish or English speaking women
* Contraindications or allergies to use of Gonadotrophins or GnRH antagonists
* TESA (testicular sperm aspiration)
* OD (oocyte donation)
* Previous inclusion in the study
D: Inclusion Criteria (pre-stimulation):

* Age up to 42 years

Exclusion Criteria (pre-stimulation):

* MESA and TESE patients
* At least one partner carrier of a chromosomal abnormality
* Egg donor cycle (sperm donor is acceptable)
* Gender selection cycles
* Thaw cycles
* Any patient who cannot have a fresh embryo transfer
* FSH above 12 or AMH less than 1

Answer: D